Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age60-90
SponsorPeking University First Hospital

About this trial

Prostate cancer ranks second among all malignances in men and has become a significant threat to men's health. Robot-assisted laparoscopic radical prostatectomy (RARP) has become a standard treatment for prostate cancer. How to improve recovery following RARP surgery is worth investigating. The enhanced recovery after surgery (ERAS) pathway involves a series of evidence-based procedures. It is aimed to reduce the systemic stress response to surgery and shorten the length of hospital stay. This randomized trial aims to investigate the impact of Enhanced Recovery After Surgery (ERAS) Pathway on early outcomes after RARP surgery.

Eligibility criteria

Qualifiers

Aged 60 years or over but below 90 years.

Scheduled to undergo robot-assisted laparoscopic radical prostatectomy (RARP) for prostate cancer.

Agree to participate in this study and give written informed consent.

Disqualifiers

Scheduled to undergo combined surgery, including RARP combined with pelvic lymph node dissection or other procedures.

American Society of Anesthesiologists (ASA) physical classification ≥IV.

Inability to receive preoperative aerobic exercise because of severe cardiovascular disease, motor system diseases (arthritis, lumbar vertebrae disease), or central nervous system diseases (epilepsy, parkinsonism).

Inability to communicate in the preoperative period because of profound dementia, deafness, or language barriers.

Trial design

Treatments tested in this trial

  • Routine care
  • ERAS management pathway

Treatment groups

54 Participants
are divided into 2 treatment groups